The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Activity of cabozantinib (XL184) in hepatocellular carcinoma patients (pts): Results from a phase II randomized discontinuation trial (RDT).
Allen Lee Cohn
No relevant relationships to disclose
Robin Katie Kelley
No relevant relationships to disclose
Tsai-Shen Yang
No relevant relationships to disclose
Wu-Chou Su
No relevant relationships to disclose
Chris Verslype
No relevant relationships to disclose
David A. Ramies
Employment or Leadership Position - Exelixis
Stock Ownership - Exelixis
Yihua Lee
Employment or Leadership Position - Exelixis
Stock Ownership - Exelixis
Xiaodong Shen
Employment or Leadership Position - Exelixis
Stock Ownership - Exelixis
Eric Van Cutsem
No relevant relationships to disclose